Mesalamine XR Shortage: What Providers and Prescribers Need to Know in 2026

If you're managing patients with ulcerative colitis, you've likely already received calls from patients unable to fill their Mesalamine XR prescriptions. The 2026 supply situation for mesalamine extended-release capsules is complex — an active back order from a major generic manufacturer, persistent pharmacy-level availability gaps, and formulary pressures that complicate prescribing decisions. This briefing covers the current landscape, clinical implications, and practical strategies to maintain treatment continuity for your UC patients.

Current Shortage Status (as of Q1 2026)

The ASHP Drug Shortage Database (updated March 24, 2026) confirms that Sun Pharmaceutical Industries' mesalamine extended-release 500 mg capsules (120-count bottles) are on back order with no estimated resupply date. Sun Pharma received FDA approval in 2022 for generic mesalamine ER capsules referencing Pentasa as the reference listed drug, making them a significant portion of the generic 500 mg ER supply.

Separately, brand-name Apriso (mesalamine 0.375 g ER capsules, Salix Pharmaceuticals/Bausch Health) and brand-name Pentasa (Takeda) are not on the FDA's active shortage list. However, pharmacy-level availability remains inconsistent due to:

Automated inventory management deprioritizing specialty maintenance medications with smaller dispensing volumes

Generic substitution practices shifting pharmacy stock entirely to generic, causing availability gaps for brand-specified prescriptions

Regional wholesale distribution gaps independent of national supply adequacy

Clinical Implications for Prescribers

The access landscape has several practical implications for your prescribing practice:

1. Prescribe Generic Mesalamine ER When Clinically Appropriate

Unless there are specific clinical reasons to require a brand-name product (e.g., patient tolerance history, insurance requirements), prescribing "mesalamine extended-release capsules" generically allows the pharmacy to source from any available FDA-approved manufacturer. Brand-specific prescriptions during a supply shortage often result in unfilled scripts when pharmacies can only stock one manufacturer's product.

2. Consider the Strength Your Patient Needs

The current ASHP shortage is specific to the 500 mg strength. The 0.375 g strength (Apriso/generic) is not in formal shortage. If your patient is in remission and the clinical indication is maintenance only, prescribing 1.5 g (four 0.375 g capsules) once daily may be a viable substitute with better near-term availability. Note that the 0.375 g capsule is only FDA-approved for maintenance of remission — not for induction in active UC.

3. Formulation Alternatives by Indication

If 500 mg ER capsules are unavailable, consider these alternatives based on your patient's clinical situation:

Active UC (induction): Lialda (mesalamine 1.2 g DR tablets) 4.8 g once daily, or Asacol HD (mesalamine 800 mg DR tablets) three times daily on empty stomach

Maintenance of remission: Lialda 2.4 g once daily, Apriso 1.5 g once daily, or Delzicol 1.6 g/day in divided doses

Cost-sensitive patients: Sulfasalazine (Azulfidine) is significantly cheaper and widely available, though with a more pronounced side effect profile in some patients

4. Renal Function Monitoring Reminder

Regardless of the mesalamine formulation you prescribe, the updated FDA label requires assessment of renal function before initiating therapy and periodically during treatment. Patients with existing renal impairment or those taking concomitant nephrotoxic drugs (including NSAIDs) require more frequent monitoring. If renal function deteriorates, discontinuation of mesalamine is recommended.

Cost and Access Considerations for Patients

Many of your mesalamine patients face significant cost barriers in addition to supply challenges:

Generic Mesalamine ER: Retail cash price averages $450–$560/month; with GoodRx or SingleCare discount cards, as low as $37–$45/month

Brand Apriso / Pentasa: Approximately $500–$700/month without insurance or manufacturer assistance

Salix Savings Card (Apriso): Eligible commercially insured patients may pay as little as $0 for the first fill, $10 for subsequent fills (max $100 benefit/fill; not valid for government insurance)

Bausch Health PAP: For uninsured/underinsured patients, Bausch Health offers a patient assistance program for Apriso

Tools to Help Your Patients Find Mesalamine XR

Consider recommending medfinder to patients who are struggling to find their medication. Patients enter their medication, dosage, and ZIP code; medfinder contacts local pharmacies to determine which ones can fill the prescription; results are texted back to the patient. This removes the burden from both patients and clinical staff and can help identify supply within a reasonable geographic radius.

Monitoring Patients During the Shortage

Patients who experience medication gaps during the shortage are at increased risk of UC flares. Advise patients to watch for early flare symptoms: increased stool frequency, rectal bleeding, urgency, and abdominal cramping. Early intervention is preferable to managing a full flare. Consider proactive outreach to high-risk patients (those with frequent flares or recent induction of remission) if you're aware they're having difficulty accessing their medication.

For more on helping your patients navigate the current supply landscape, see: How to help your patients find Mesalamine XR in stock: a provider's guide.